Natural Products Insider

NOV-DEC 2018

INSIDER is the leading information source for marketers, manufacturers and formulators of dietary supplements, healthy foods and cosmeceuticals. Since 1997, INSIDER has been serving the needs of the global nutrition industry.

Issue link:

Contents of this Issue


Page 20 of 166

16 INSIDER November/December 2018 Olive oil polyphenols (standardized by their content of hydroxytyrosol [HT] and its derivatives) have been recognized by the European Food Safety Authority (EFSA) for protection of LDL particles from oxidative damage. 3 The PREDIMED trial, which looked at the long-term effects of a Mediterranean diet in people at high risk of a cardiovascular event, further supported the heart healthy benefi ts of olive oil polyphenols. 4 Over fi ve years, Mediterranean diet participants who supplemented with extra-virgin olive oil had a 30 percent decrease in the rate of cardiovascular events compared to those on a low-fat diet. Mediterranean dieters also had improved blood pressure, insulin sensitivity, lipid profi les, lipoprotein particles, infl ammation, oxidative stress and carotid atherosclerosis. Euromed's Spanish olive fruit extract (SOFE) standardized for high HT at a 500 mg dose improved arterial elasticity and reduced triglycerides per Cardio-Ankle Vascular Index scores. 5 It's well known that the cholesterol- lowering properties of phytosterols are due, at least in part, to an extensive blockade of intestinal absorption of cholesterol. 6 In a study of a dispersible form of phytosterols (as Lipophytol™, from Lipofoods), Lipofoods with the Technological Center of Nutrition and Health in Spain found both raw phytosterols and its microencapsulated derivative (Lipophytol) act similarly to increase the excretion of cholesterol. 7 However, it was also shown that raw phytosterols did not ameliorate hypertriglyceridemia to the same extent as Lipophytol. Stauber Performance Ingredients is the exclusive distributor of Lipophytol. Red yeast rice extract has been promoted primarily for its potential to impact blood lipids. New research conducted on ANKASCIN ® 568-R (from SunWay Biotech), an extract of fermented products of patented functional red yeast (Monascus purpureus NTU 568), found its active ingredients—monascin and ankafl avin—can reduce total and LDL cholesterol, 8 reduce blood glucose 9 and decrease systolic and diastolic blood pressure. 10 The ingredient is produced through solid-state fermentation and does not contain monacolin K, which has raised safety concerns for other red yeast rice ingredients. A tomato nutrient complex (Cardiomato™, from Lycored) was shown to reduce oxidized LDL. 11 The study suggested that after two weeks of supplementation, a signifi cant reduction in this specifi c form of oxidized cholesterol was achieved as well as a metabolic profi le improvement following the meal. Research suggested curcumin (as CurcuWIN, from OmniActive Health Technologies) is a potential strategy for the early prevention of CVD and its associated costs. 12 "Using fl ow-mediated dilation to assess endothelial function, CurcuWIN signifi cantly increased fl ow mediated dilation in healthy subjects that may potentially reduce CVD risk by as much as 50 percent," explained Brian Appell, marketing manager, activation at OmniActive Health Technologies. The naturally occurring carotenoid astaxanthin has shown benefi ts to many areas of health, including cardiovascular health. One study showed astaxanthin derived from the algae Haematococcus pluvialis (as AstaReal ® ) signifi cantly reduced triglyceride at doses of 12 and 18 mg/d, while doses of 6 and 12 mg/d signifi cantly increased HDL cholesterol in subjects ages 25 to 60 with fasting serum triglyceride levels between 120 to 200 mg/dl and without diabetes and hypertension. 13 AstaReal also reduced systolic and diastolic blood pressure in subjects with increased oxidative stress 14 Omega-3s: A Matter of Heart Omega-3s have been extensively studied for their benefi ts to the heart. Though most publications report positive outcomes, conclusions among meta- analyses looking at omega-3s and coronary heart disease (CHD) outcomes have been inconsistent over the last two years. For example, a 2016 publication concluded there was low-strength evidence showing no association between the omega-3s eicosapentaenoic acid (EPA)/ docosahexaenoic acid (DHA) consumption and CHD death. 15 However, this was based on only fi ve randomized controlled trials (RCTs) reporting cardiac death (combined CHD and other cardiac death), and no statistics were provided. A 2018 meta-analysis published in JAMA questioned the effects of omega-3s on cardiovascular risk factors, concluding, "This meta-analysis demonstrated that omega-3 fatty acids had no signifi cant association with fatal or nonfatal coronary heart disease or any major vascular events. 16 It provides no support for current recommendations for the use of such supplements in people with a history of coronary heart disease." Importantly, the study did not indicate there was no risk reduction, but did mention that there were no statistically signifi cant associations and that it does not support current guidelines. Among recent positive studies is a 2017 meta-analysis demonstrating that consumption of EPA and DHA reduced the risk of cardiac death by a statistically signifi cant average of 8 percent, with an even greater (17 percent) risk reduction in groups who had elevated triglycerides or LDL cholesterol. 17 The greatest reduction in cardiac death rates—almost 30 percent— was observed in trials that utilized dosages of more than 1 g/d EPA+DHA. In a 2018 pilot human trial of 36 men and women, systolic blood pressure was signifi cantly reduced among subjects who consumed concentrated fi sh oil (from AlaskOmega/Organic Technologies) offering Supplements: Heart Health

Articles in this issue

Archives of this issue

view archives of Natural Products Insider - NOV-DEC 2018